Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease

B L Herrmann 1,2, K W Schmid 3, R Goerges 4, M Kemen 5 and K Mann 1

1Department of Endocrinology and Division of Laboratory Research, University Duisburg-Essen, Essen, Germany, 2Division of Endocrinology, Diabetology and Laboratory, Technology Center Bochum, Universitätsstraße 142, D-44799 Bochum, Germany, Departments of 3Pathology and Neuropathology and 4Nuclear Medicine, University Duisburg-Essen, Essen, Germany and 5Department of Visceral Surgery, Ev. Hospital Herne, Herne, Germany

(Correspondence should be addressed to B L Herrmann at Division of Endocrinology, Diabetology and Laboratory, Technology Center Bochum; Email: herrmann@endokrinologie-tzr.de)

Abstract

Context: Serum calcitonin (hCT) measurement may be useful for detecting medullary thyroid carcinoma (MTC), but the routine use of hCT after pentagastrin stimulation to screen patients with nodular thyroid disease remains controversial.

Patients: A total of 1007 patients (567 females and 440 males) with nodular thyroid disease and a mean age of 55 ± 14 (mean ± s.d.) years were included in the study. All patients did not have impaired renal function, bacterial infection, alcohol and drug abuse, pseudohypoparathyroidism, or proton-pump inhibitor therapy. Individuals referred with known elevation of hCT, Graves’ disease, or autoimmune thyroid disease were not considered or included in this investigation.

Methods: Serum hCT levels were determined under basal conditions, and when basal values were <10 and >100 pg/ml, testing was repeated after pentagastrin stimulation. Patients with basal hCT levels > 100 pg/ml were referred for surgery. hCT levels > 10 pg/ml were increased in 17 patients (1.7%). One patient had a basal hCT level of 4400 pg/ml with a histological confirmation of a MTC. In this patient, pentagastrin test was not performed. Sixteen patients with basal hCT between 10 and 100 pg/ml underwent pentagastrin-stimulated hCT measurement. Of 16 patients, 4 had stimulated hCT > 100 pg/ml. Of 17 patients with hCT > 10 pg/ml, 2 had MTC, and of 17 patients, 3 had C-cell hyperplasia. In total, two patients (0.20%) had a histologically verified MTC.

Conclusions: Basal hCT measurement together with pentagastrin-stimulated hCT measurement in cases of basal hCT > 10 pg/ml detects MTC in 0.20% of patients with nodular thyroid disease. Whether this high incidence of MTC has major implications or not has to be discussed, but it should be considered as a useful and recommended tool for early detection of MTC and to save patients’ life.

European Journal of Endocrinology

Introduction

In Germany, thyroid nodules are frequently observed in clinical practice with a prevalence of about 23% (1). Calcitonin (CT) is a 32-amino acid polypeptide secreted mainly by the parafollicular C-cells of the thyroid, and medullary thyroid carcinomas (MTCs) are derived from the same cells, and they uniformly express CT (2). MTC reportedly accounts for ~ 5% of all the thyroid carcinomas, and is sporadic in 50–78% of the cases (3–7). MTC is characterized by early micrometastasis and a lack of curative non-surgical treatment, so that early diagnosis is desirable. By the time patients with MTC present with clinical disease, the condition is usually metastatic and cannot be cured by surgery.

An elevated serum calcitonin (hCT) value in patients with thyroid nodules after exclusion of potential conditions (impaired renal function, bacterial infection, alcohol and drug abuse, pseudohypoparathyroidism, or proton-pump inhibitor therapy) needs re-testing after an i.v. pentagastrin administration. HCT, stored in dense-cored secretory granules, can be released into the bloodstream with the synthetic analog gastrin pentapeptide (pentagastrin) (8). Pentagastrin binds to the extracellular domain of the transmembrane cholecystokinin-B/gastrin receptor, and stimulates hCT secretion (9). Therefore, hCT measurements after pentagastrin testing are used for biochemical diagnosis of primary and/or occult MTCs.

In spite of the fact that many European consensus groups and societies recommended hCT measurement
as the screening parameter that detects medullary thyroid cancer, the majority of the physicians do not routinely use this test (10, 11). In the last few years, several studies revealed different upper limits of basal hCT values to detect MTC and to reduce false-positive cases (12–15). The present study sheds further light on the hCT measurement and its testing after pentagastrin stimulation in patients with thyroid nodule disease.

**Patients and methods**

A total of 1007 patients (567 females and 440 males, mean age of 55±14 years, median 56 years) with nodular thyroid disease found by sonography living in central Germany, an area with endemic goiter due to previous iodine deficiency, were included in the study between June 2005 and September 2009. In one single center (Division of Endocrinology, Technology Center Bochum, Germany), patients with known or unknown thyroid disease underwent ultrasound. In the case of thyroid nodules, measurement of hCT was done, and it was the first hCT determination in every patient. Individuals referred with known elevation of hCT, Graves’ disease, or autoimmune thyroid disease were not considered or included in this investigation.

All patients did not have impaired renal function, bacterial infection, alcohol and drug abuse, pseudo-hypoparathyroidism, or proton-pump inhibitor therapy. hCT was measured at the Institution of Endocrinology and Laboratory in the Technology Center of Bochum, Germany, using the solid-phase, enzyme-labeled, two-site chemiluminescent assay with the Immulite 2000 (Siemens Immulite 2000, Munich, Germany). When basal CT values were ≥10 and <100 pg/ml, testing was repeated 2 and 5 min after pentagastrin stimulation (with an i.v. bolus injection of 0.5 μg pentagastrin (Peptavlon; Laboratoires SERB, Paris, France) per kilogram body weight) at the same institution. Basal or stimulated levels >100 pg/ml were referred for surgery.

In the case of patients with elevated pentagastrin-stimulated hCT levels >100 pg/dl or basal hCT >100 pg/dl, total thyroidectomy was performed. Moreover, both recurrent nerves were dissected carefully, and a systemic microdissection of the central lymph node compartments along both the nerves from the upper thoracic outlet up to the larynx was done. Germline mutations of the RET proto-oncogene were investigated in all the patients with MTC.

All patients had given informed consent to the diagnostic and therapeutic procedures. For retrospective analysis of the existing datasets from routine patient care, no institutional review board approval is required under the German law and applicable institutional regulations.

**Results**

hCT levels >10 pg/ml were increased in 17 patients (1.7%; Fig. 1). One patient had a basal hCT level of 4400 pg/ml with a histological confirmation of a MTC (Table 1). In this patient, pentagastrin test was not performed. Sixteen patients with basal hCT between 10 and 100 pg/ml underwent pentagastrin-stimulated hCT measurement (Fig. 2). The mean increase of hCT after pentagastrin stimulation (Table 1) was 4.6-fold (range 2.6–7.9) in patients 1–12, 8.8-fold (range 8.5–8.8) in patients 13–15 (C-cell hyperplasia, CCH), and 25-fold in patient 16 (MTC).

All patients with basal or stimulated hCT >100 pg/ml could be observed for follow-up, and they underwent total thyroidectomy as well as the systemic microdissection of the defined regions. No permanent paralysis of the recurrent nerves was observed. One patient had permanent hypoparathyroidism. Of 17 patients, 5 had basal/stimulated hCT >100 pg/ml, 2 had MTC, and 3 had CCH. In total, two patients (0.20%) had histologically verified MTC. No mutation of the RET proto-oncogene could be detected, so that the two MTCs were classified as sporadic (16, 17).

The age of the males with MTC was 76 years and that of the females was 66 years. Basal hCT levels of the patients were 58 and 4400 pg/ml. Postoperative basal hCTs of the patients with CCH were <2 pg/ml, and those of patients with MTC were 2 and 11 pg/ml (Table 1). In the last patient (no. 16), stimulated hCT after pentagastrin testing increased to 200 pg/ml. In patient no. 17 with preoperative basal hCT of 4400 pg/ml, postoperative pentagastrin-stimulated hCT was 21 pg/ml. Tumor size of patient no. 16 was 3 mm and of patient no. 17 with MTC was 20 mm. The five patients with CCH and MTC were diagnosed by
histology by two different pathologists and were verified by a third pathologist, who had observed tissues from all the five patients.

To date, positron emission tomography investigation using fluorodeoxyglucose as the most sensitive and specific single modality could not detect metastases in this patient (18). Patients with stimulated hCT $>100$ pg/ml did not undergo surgery of the thyroid, and were under follow-up with re-testing.

**Discussion**

The present study has shown that hCT screening reveals one case of MTC among 500 patients with thyroid nodule disease. The present MTC prevalence of 0.20% in patients with thyroid nodule disease is lower, but it is also similar to that reported in some previous studies (0.33–0.40%), in which patients with known hypercalcitonemia were excluded (13, 19, 20). A higher prevalence rate has been reported in several previous studies, which may be due to patient selection and/or to different normal range values employed, which were determined by RIA or IRMA (14, 21–23). Vierhapper et al. have shown that before hCT screening was instituted, the diagnosis of MTC was made in 1 of 900 patients with thyroid nodule disease referred to their clinic (13). The determination of basal hCT was responsible for the threefold increase in diagnosing MTC. Moreover, in the study by Vierhapper et al. basal hCT $<10$ pg/ml was stimulated by pentagastrin $>100$ pg/ml with histological confirmation of MTC in one patient (13). In our study, all patients with basal hCT $>15$ pg/ml and pentagastrin-stimulated hCT $>100$ pg/ml had confirmed CCH or MTC. On the other hand, in another study by Rink et al. one patient had basal hCT $<15$ pg/ml and we have performed pentagastrin testing in all patients with hCT $>10$ pg/ml without losing any of these patients to follow-up. Of 16 patients, 4 had hCT $>100$ pg/ml after pentagastrin stimulation and underwent thyroidectomy, resulting in one MTC and two CCHs. In a recent study by Rink et al. the increase of the upper limit for basal hCT to 15 pg/ml instead of to 10 pg/ml, significantly reduced the number of false-positive cases (12). None of these patients with basal hCT $<10$ pg/ml had MTC. In our study, all patients with basal hCT $>15$ pg/ml and pentagastrin-stimulated hCT $>100$ pg/ml had confirmed CCH or MTC. On the other hand, in another study by Vierhapper et al. basal hCT $<15$ pg/ml was stimulated by pentagastrin $>100$ pg/ml with histological confirmation of MTC in one patient (13). Moreover, in the study by Rink et al. one patient had basal hCT $>15$ pg/ml and

<table>
<thead>
<tr>
<th>No.</th>
<th>Age (years)</th>
<th>Sex (M/F)</th>
<th>hCTb (pg/ml)</th>
<th>hCTs (pg/ml)</th>
<th>Sono (mm)</th>
<th>FNAB</th>
<th>Histology</th>
<th>Staging</th>
<th>hCTpost (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>43</td>
<td>M</td>
<td>10.1</td>
<td>27</td>
<td>7</td>
<td>7</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>48</td>
<td>M</td>
<td>10.2</td>
<td>33</td>
<td>18</td>
<td>18</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>M</td>
<td>10.4</td>
<td>45</td>
<td>14</td>
<td>14</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>46</td>
<td>M</td>
<td>11</td>
<td>29</td>
<td>9</td>
<td>9</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>58</td>
<td>M</td>
<td>11</td>
<td>66</td>
<td>11</td>
<td>11</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>53</td>
<td>M</td>
<td>11</td>
<td>83</td>
<td>9</td>
<td>9</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>44</td>
<td>M</td>
<td>12</td>
<td>35</td>
<td>5</td>
<td>5</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>41</td>
<td>M</td>
<td>12</td>
<td>95</td>
<td>8</td>
<td>8</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>71</td>
<td>M</td>
<td>13</td>
<td>99</td>
<td>30</td>
<td>30</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>61</td>
<td>M</td>
<td>15</td>
<td>39</td>
<td>9</td>
<td>9</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>68</td>
<td>M</td>
<td>18</td>
<td>64</td>
<td>25</td>
<td>25</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>67</td>
<td>M</td>
<td>18</td>
<td>73</td>
<td>8</td>
<td>8</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>71</td>
<td>M</td>
<td>18</td>
<td>160</td>
<td>17</td>
<td>17</td>
<td>Not done</td>
<td>CCH</td>
<td>$&lt;2$</td>
</tr>
<tr>
<td>14</td>
<td>56</td>
<td>M</td>
<td>19</td>
<td>176</td>
<td>28</td>
<td>28</td>
<td>Negative</td>
<td>CCH</td>
<td>$&lt;2$</td>
</tr>
<tr>
<td>15</td>
<td>51</td>
<td>M</td>
<td>38</td>
<td>322</td>
<td>10</td>
<td>10</td>
<td>Not done</td>
<td>CCH</td>
<td>$&lt;2$</td>
</tr>
<tr>
<td>16</td>
<td>76</td>
<td>M</td>
<td>58</td>
<td>1471</td>
<td>8</td>
<td>MTC</td>
<td>MTC</td>
<td>pT3, M0, N1</td>
<td>11</td>
</tr>
<tr>
<td>17</td>
<td>66</td>
<td>F</td>
<td>4400</td>
<td>Not done</td>
<td>30</td>
<td>Not done</td>
<td>MTC</td>
<td>pT2, M0, N0</td>
<td>2</td>
</tr>
</tbody>
</table>

Age (years), M, male; F, female; hCTb, basal hCT (pg/ml); hCTs, maximal pentagastrin-stimulated hCT (pg/ml); Sono, size of the dominant nodule by sonography (mm); FNAB, fine-needle aspiration; CCH, C-cell hyperplasia; hCTpost, postoperative hCT (pg/ml).

We have performed pentagastrin testing in all patients with hCT $>10$ pg/ml without losing any of these patients to follow-up. Of 16 patients, 4 had hCT $>100$ pg/ml after pentagastrin stimulation and underwent thyroidectomy, resulting in one MTC and two CCHs. In a recent study by Rink et al. the increase of the upper limit for basal hCT to 15 pg/ml, instead of to 10 pg/ml, significantly reduced the number of false-positive cases (12). None of these patients with basal hCT $<10$ pg/ml had MTC. In our study, all patients with basal hCT $>15$ pg/ml and pentagastrin-stimulated hCT $>100$ pg/ml had confirmed CCH or MTC. On the other hand, in another study by Vierhapper et al. basal hCT $<15$ pg/ml was stimulated by pentagastrin $>100$ pg/ml with histological confirmation of MTC in one patient (13). Moreover, in the study by Rink et al. one patient had basal hCT $>15$ pg/ml and...
pentagastrin-stimulated hCT of 81 pg/dl with histologically confirmed MTC, so that the cutoff levels of pentagastrin-stimulated hCT > 100 pg/dl did not have 100% sensitivity (12). Moreover, stimulated hCT > 100 pg/ml cannot differentiate between CCH and MTC, considering the histological results with CCH of three of our patients with stimulated hCT between 176 and 322 pg/ml.

In a recent study by Doyle et al. stimulated hCT after the administration of high-dose calcium in comparison to that after the administration of pentagastrin was investigated. Calcium seemed to be a more potent and better tolerated hCT stimulator than pentagastrin, and it can be considered as a new and valid alternative in future (27).

Moreover, men and women differ in thyroid C-cell mass and CT secretion. To increase the positive predictive value, the existence of a gender-specific threshold predicting sporadic occult MTC (28) has to be discussed and considered.

Nevertheless, the risk of MTC is obviously very low in the range of 10–15 pg/dl of basal hCT and hCT < 100 pg/dl after pentagastrin stimulation. This is in accordance with the upper limit of the normal range of 100 pg/dl, as published in the German consensus recommendation of 2004 (10). The recommended yearly follow-up investigations in patients with pentagastrin stimulation of hCT between 50 and 100 pg/dl can shed new light on this issue. Lowering of this threshold for surgery may lead to the referral of many patients to unnecessary operations. Thus, the definition of 100 pg/dl as a therapeutical threshold reflects a clinical compromise, balancing overtreatment and undertreatment in these patients.

CCH was observed in three patients (0.3%), which was similar to previous observations (0.5%) (13). CCH is characterized by an increased quantity of C-cells within the thyroid, commonly defined as > 50 C-cells per low-power field in histological examination, and it has been considered as a carcinoma in situ of the thyroid parafollicular cells in hereditary MTC (29, 30). In contrast, the clinical relevance of sporadic CCH outside hereditary MTC remains unclear, and the hypothetical role of CCH as a risk factor for sporadic C-cell malignancy is not supported by available evidence (11, 31).

Determination of serum hCT is more sensitive than fine-needle aspiration for MTC detection (14, 32). False-negative reports in fine-needle aspiration may occur in the case of thyroid malignancies, both in large nodules and in microcarcinomas, tumors < 10 mm in diameter (33). Nevertheless, fine-needle aspiration should be recommended considering the fact that one of the two MTCs in our study was 3 mm, and could be detected positively by cytology.

The age of our patients with MTC (66 and 76 years) is higher than the known mean age of patients with sporadic MTC (46 years), which may be due to the mean age of the patients in our institution and may not reflect a more benign form of MTC in these patients discovered by screening (34).

Whether tumors of small size could stay potentially in their tumor stage for a very long time or may develop metastases cannot be answered, but this has to be considered. It has been shown that preoperative hCT levels correlated with the postoperative tumor size in patients with MTC, and its relationship was straighter in familial forms than in sporadic forms (23, 35). Both of our patients with MTC had the sporadic form, which could be an explanation for the missing correlation of hCT levels and tumor size. One patient with 20-mm tumor size without metastases could be cured by surgery, although the preoperative hCT was very high (4.440 pg/ml) with the suggested metastatic disease. But postoperative basal and pentagastrin-stimulated hCT < 10 pg/ml documented the cure of this patient. The other patient with a 3-mm tumor size had lymph node metastases already and could not be cured by surgery (preoperative stimulated hCT > 1.471 pg/ml), so that the initial tumor size could not predict metastases.

In conclusion, primarily basal hCT measurement is recommended in patients with thyroid nodule disease. It has been shown that one case of MTC among 500 patients with thyroid nodule disease could be detected in an early tumor stage. Whether this high incidence of MTC has major implications or not has to be discussed, but it should be considered as a useful and recommended tool for early detection of MTC and to save the patients’ life. Screening using the cost-effective hCT measurement can help in the cure of the overwhelming majority of these patients by surgery.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

Calcitonin screening in nodular thyroid disease


